Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment
Vision · 18.11.2025 · 9 (4) · 95
DOI: 10.3390/vision9040095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vision, online erschienen am 18.11.2025. Verfasst von Jessica A Cao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Retina Consultants of Texas, Bellaire, TX 77401, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Texas Retina Research Foundation (TRRF), Houston, Texas.
Abstract (Originalsprache)
This retrospective study evaluated changes in ocular characteristics and retinal pigment epithelium (RPE) and photoreceptor ellipsoid zone (EZ) depletion rates before and after intravitreal pegcetacoplan initiation in clinical practice. A total of 168 eyes from 110 patients with GA secondary to age-related macular degeneration (AMD) who received at least 3 pegcetacoplan injections were included. Data was collected from 5 years before to 9 months after pegcetacoplan initiation. RPE and EZ depletion areas were measured using an automated artificial intelligence (AI) algorithm on optical coherence tomography (OCT) images. At baseline, 76 eyes (45.2%) had concurrent neovascular AMD (nAMD), with mean RPE and EZ depletion areas of 3.3 mm2 and 4.9 mm2, respectively. By pegcetacoplan initiation, these increased to 8.6 mm2 and 11.2 mm2, respectively, with 151 eyes (89.9%) having concurrent nAMD and 155 eyes (92.3%) having subfoveal GA. Pre-treatment to post-treatment RPE and EZ square root depletion rates decreased from 0.25 mm/year to 0.096 mm/year, and 0.26 mm/year to 0.049 mm/year, respectively. Mean best-recorded visual acuity (BRVA) worsened by 0.05 logMAR annually before and after treatment. These real-world findings align with data from the pegcetacoplan phase 3 trials, showing reduced RPE and EZ depletion rates without changes in rates of BRVA loss. Additional studies are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Retina Consultants of Texas, Bellaire, TX 77401, USA.
- Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Ikerian AG, 3010 Bern, Switzerland.
- Department of Ophthalmology, Rush University Medical Center and Illinois Retina Associates, Chicago, IL 60612, USA.
- Blanton Eye Institute, Houston Methodist Hospital, Houston, TX 77030, USA.
ORCID-Profile: Jessica A Cao, Avery W Zhou, Gail M Teagle, Ryan A Sahraravand, Calvin W Wong, Sandro De Zanet, Sagar B Patel, Samuel A Minaker, Hasenin Al-Khersan, Charles C Wykoff
Förderung
- Texas Retina Research Foundation (TRRF), Houston, Texas
Zitieren
APA
Cao, J. A., Zhou, A. W., Teagle, G. M., Baumann, L. M., Sahraravand, R. A., Wong, C. W., De Zanet, S., Jovic, N., Steiner, P., Patel, S. B., Minaker, S. A., MacCumber, M. W., Brown, D. M., Al-Khersan, H., & Wykoff, C. C. (2025). Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment. Vision, 9(4), 95. https://doi.org/10.3390/vision9040095
Vancouver
Cao JA, Zhou AW, Teagle GM, Baumann LM, Sahraravand RA, Wong CW, et al. Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment. Vision. 2025;9(4):95. doi:10.3390/vision9040095
BibTeX
@article{Cao2025,
author = {Cao, Jessica A and Zhou, Avery W and Teagle, Gail M and Baumann, Liisa M and Sahraravand, Ryan A and Wong, Calvin W and De Zanet, Sandro and Jovic, Natasa and Steiner, Patrick and Patel, Sagar B and Minaker, Samuel A and MacCumber, Mathew W and Brown, David M and Al-Khersan, Hasenin and Wykoff, Charles C},
title = {Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment},
journal = {Vision},
year = {2025},
volume = {9},
number = {4},
pages = {95},
doi = {10.3390/vision9040095}
}
EUVIMED